Crossmark

Safety and Effectiveness Analyses of Dolutegravir/Lamivudine in Patients with HIV: 2-Year Report of Post-Marketing Surveillance in Japan

Crossref DOI link: https://doi.org/10.1007/s12325-023-02459-4

Published Online: 2023-02-25

Published Print: 2023-04

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Tofukuji, Ayano https://orcid.org/0000-0002-3583-0843
Hongo, Haruyuki https://orcid.org/0000-0001-5076-3717
Nagao, Takako https://orcid.org/0000-0002-1154-7090
Sebata, Akemi

Suzuki, Miwako

Maeno, Yuko

Kurosaki, Eiji

Fukuda, Akiko https://orcid.org/0000-0001-5855-2084
Watanabe, Tomoyuki
License Information

Text and Data Mining valid from 2023-02-25

Version of Record valid from 2023-02-25
More Information

Article History

Received: 6 December 2022

Accepted: 10 February 2023

First Online: 25 February 2023